Evidence map›Paper›PMID 35563269›Full record

ArticleInternational journal of molecular sciences2022

miR-196b-5p and miR-107 Expression Differentiates Ocular Sebaceous Carcinoma from Squamous Cell Carcinoma of the Conjunctiva.

Ronald O B de Keizer, Anne L M Vriends, Gijsbert J Hötte, Dion A Paridaens, Erik A C Wiemer, Robert M Verdijk

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Role of epigenetics in corneal health and disease.Progress in retinal and eye research · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ronald O B de KeizerRotterdam Eye Hospital, Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands.
Anne L M VriendsDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Gijsbert J HötteRotterdam Eye Hospital, Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands.
Dion A ParidaensRotterdam Eye Hospital, Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands.
Erik A C WiemerDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-0673-7236
Robert M VerdijkRotterdam Eye Hospital, Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands.ORCID 0000-0003-1437-214X
Erasmus MC · NLErasmus MC Cancer Institute · NLRotterdam Eye Hospital · NL

Funding

Stichting Wetenschappelijk Onderzoek het Oogziekenhuis SSWOO2018S12
6 · The paper itself

Abstract

An Ocular Sebaceous Carcinoma (OSC) is a rare malignant tumor for which initial clinical and pathological diagnosis is often incorrect. OSCs can mimic Squamous Cell Carcinomas of the Conjunctiva (SCCC). The aim of this study was to find microRNA biomarkers to distinguish OSCs and SCCCs from normal tissue and from each other. Clinical OSC and SCCC case files and the corresponding histopathological slides were collected and reviewed. Micro dissected formalin-fixed paraffin-embedded tumor and control tissues were subjected to semi-high throughput microRNA profiling. MicroRNA expression distinguishes OSCs and SCCCs from corresponding control tissues. Selected differentially expressed miRNAs were validated using single RT-PCR assays. No prognostic miRNAs could be identified that reliably predict SCCC metastasis or OSC recurrence. A comparison between OSCs (n = 14) and SCCCs (n = 18) revealed 38 differentially expressed microRNAs (p < 0.05). Differentially expressed miRNAs were selected for validation in the discovery cohort and an independent validation cohort (OSCs, n = 11; SCCCs, n = 12). At least two miRNAs, miR-196b-5p (p ≤ 0.05) and miR-107 (p ≤ 0.001), displayed a statistically significant differential expression between OSCs and SCCCs with miR-196b-5p upregulated in SCCCs and miR-107 upregulated in OSCs. In the validation cohort, microRNA miR-493-3p also showed significant upregulation in SCCCs when compared to OSCs (p ≤ 0.05). ROC analyses indicated that the combined miR-196b-5p and miR-107 expression levels predicted OSCs with 90.0% sensitivity and 83.3% specificity. In conclusion, the combined testing of miR-196b-5p and miR-107, can be of additional use in routine diagnostics to discriminate OSCs from SCCCs.

Indexed as

Carcinoma, Squamous CellEye NeoplasmsGene Expression Regulation, NeoplasticHead and Neck NeoplasmsMicroRNAsBiomarkers, TumorConjunctivaGene Expression ProfilingHumansSquamous Cell Carcinoma of Head and NeckBiomarkers, TumorMicroRNAsMIRN107 microRNA, humanMIRN196 microRNA, humanMIRN493 microRNA, humanconjunctivaeyelidmicroRNAOcular Sebaceous Carcinoma (OSC)Ocular Surface Squamous Neoplasm(OSSN)Squamous Cell Carcinoma of the Conjunctiva (SCCC)

Identifiers

PMID35563269
PMCPMC9102373
OpenAlexW4225005269

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.